Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Early detection of hepatocellular carcinoma (HCC) is critical for improving access to curative therapies, yet current surveillance with ultrasound and alpha-fetoprotein (AFP) has suboptimal sensitivity, particularly in...
Introduction: Choosing the optimal first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains challenging because reliable predictive biomarkers are lacking. This study evaluated whether the Vessels Encapsulating Tumor Clusters...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools...
Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility...
Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of...
Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major...
Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective...
Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients...
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality among patients with chronic liver disease and cirrhosis. Outcomes are substantially better when HCC is detected at...
PRISM is one of the largest prospective real-world studies evaluating systemic therapy for unresectable hepatocellular carcinoma in routine clinical practice across Japan. This analysis reports outcomes from the...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.